{"title":"白细胞介素-35:控制糖尿病前期和慢性炎症性 1 型自身免疫性糖尿病的关键因素。","authors":"Ratul Chakraborty, Ashis Kumar Mukherjee, Asis Bala","doi":"10.4239/wjd.v15.i10.2147","DOIUrl":null,"url":null,"abstract":"<p><p>Interleukin-35 (IL-35) is a novel protein comprising IL-12α and IL-27β chains. The IL12A and <i>EBI3</i> genes are responsible for its production. The study of IL-35 has experienced a substantial increase in interest in recent years, as demonstrated by many research papers. Recent clinical studies have shown that individuals who do not have a C-peptide have notably reduced amounts of IL-35 in their blood serum. This is accompanied by a drop in the percentage of IL-35<sup>+</sup> Treg cells, regulatory B cells, and CD8<sup>+</sup> FOXP3<sup>+</sup> cells that produce IL-35. This article em-phasizes the potential significance of IL-35 expression in governing the immune response and its involvement in chronic inflammatory autoimmune diabetes in pancreatic inflammation. It demonstrates IL-35's ability to regulate cytokine proportions, modulate B cells, and protect against autoimmune diabetes. However, further investigation is necessary to ascertain the precise mechanism of IL-35, and meticulous planning is essential for clinical studies.</p>","PeriodicalId":48607,"journal":{"name":"World Journal of Diabetes","volume":"15 10","pages":"2147-2151"},"PeriodicalIF":4.2000,"publicationDate":"2024-10-15","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11525726/pdf/","citationCount":"0","resultStr":"{\"title\":\"Interleukin-35: A key player managing pre-diabetes and chronic inflammatory type 1 autoimmune diabetes.\",\"authors\":\"Ratul Chakraborty, Ashis Kumar Mukherjee, Asis Bala\",\"doi\":\"10.4239/wjd.v15.i10.2147\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<p><p>Interleukin-35 (IL-35) is a novel protein comprising IL-12α and IL-27β chains. The IL12A and <i>EBI3</i> genes are responsible for its production. The study of IL-35 has experienced a substantial increase in interest in recent years, as demonstrated by many research papers. Recent clinical studies have shown that individuals who do not have a C-peptide have notably reduced amounts of IL-35 in their blood serum. This is accompanied by a drop in the percentage of IL-35<sup>+</sup> Treg cells, regulatory B cells, and CD8<sup>+</sup> FOXP3<sup>+</sup> cells that produce IL-35. This article em-phasizes the potential significance of IL-35 expression in governing the immune response and its involvement in chronic inflammatory autoimmune diabetes in pancreatic inflammation. It demonstrates IL-35's ability to regulate cytokine proportions, modulate B cells, and protect against autoimmune diabetes. However, further investigation is necessary to ascertain the precise mechanism of IL-35, and meticulous planning is essential for clinical studies.</p>\",\"PeriodicalId\":48607,\"journal\":{\"name\":\"World Journal of Diabetes\",\"volume\":\"15 10\",\"pages\":\"2147-2151\"},\"PeriodicalIF\":4.2000,\"publicationDate\":\"2024-10-15\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11525726/pdf/\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"World Journal of Diabetes\",\"FirstCategoryId\":\"3\",\"ListUrlMain\":\"https://doi.org/10.4239/wjd.v15.i10.2147\",\"RegionNum\":3,\"RegionCategory\":\"医学\",\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q1\",\"JCRName\":\"ENDOCRINOLOGY & METABOLISM\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"World Journal of Diabetes","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.4239/wjd.v15.i10.2147","RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"ENDOCRINOLOGY & METABOLISM","Score":null,"Total":0}
引用次数: 0
摘要
白细胞介素-35(IL-35)是一种由 IL-12α 和 IL-27β 链组成的新型蛋白质。IL12A 和 EBI3 基因负责其生产。近年来,人们对 IL-35 的研究兴趣大增,许多研究论文都证明了这一点。最近的临床研究表明,没有 C 肽的人血清中 IL-35 的含量明显减少。与此同时,产生 IL-35 的 IL-35+ Treg 细胞、调节性 B 细胞和 CD8+ FOXP3+ 细胞的比例也有所下降。这篇文章强调了IL-35表达在调节免疫反应中的潜在意义,以及它在慢性炎症性自身免疫性糖尿病胰腺炎症中的参与作用。它证明了 IL-35 能够调节细胞因子的比例、调节 B 细胞并防止自身免疫性糖尿病。然而,要确定 IL-35 的确切机制还需要进一步的研究,临床研究也必须有周密的计划。
Interleukin-35: A key player managing pre-diabetes and chronic inflammatory type 1 autoimmune diabetes.
Interleukin-35 (IL-35) is a novel protein comprising IL-12α and IL-27β chains. The IL12A and EBI3 genes are responsible for its production. The study of IL-35 has experienced a substantial increase in interest in recent years, as demonstrated by many research papers. Recent clinical studies have shown that individuals who do not have a C-peptide have notably reduced amounts of IL-35 in their blood serum. This is accompanied by a drop in the percentage of IL-35+ Treg cells, regulatory B cells, and CD8+ FOXP3+ cells that produce IL-35. This article em-phasizes the potential significance of IL-35 expression in governing the immune response and its involvement in chronic inflammatory autoimmune diabetes in pancreatic inflammation. It demonstrates IL-35's ability to regulate cytokine proportions, modulate B cells, and protect against autoimmune diabetes. However, further investigation is necessary to ascertain the precise mechanism of IL-35, and meticulous planning is essential for clinical studies.
期刊介绍:
The WJD is a high-quality, peer reviewed, open-access journal. The primary task of WJD is to rapidly publish high-quality original articles, reviews, editorials, and case reports in the field of diabetes. In order to promote productive academic communication, the peer review process for the WJD is transparent; to this end, all published manuscripts are accompanied by the anonymized reviewers’ comments as well as the authors’ responses. The primary aims of the WJD are to improve diagnostic, therapeutic and preventive modalities and the skills of clinicians and to guide clinical practice in diabetes. Scope: Diabetes Complications, Experimental Diabetes Mellitus, Type 1 Diabetes Mellitus, Type 2 Diabetes Mellitus, Diabetes, Gestational, Diabetic Angiopathies, Diabetic Cardiomyopathies, Diabetic Coma, Diabetic Ketoacidosis, Diabetic Nephropathies, Diabetic Neuropathies, Donohue Syndrome, Fetal Macrosomia, and Prediabetic State.